An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis

Microbiology

Volumn 148, Issue 10, 2002, Pages 2929-2936

  Turner, David J ^a   Hoyle, Stefan L ^a   Snewin, Valerie A ^a   Gares, Marie Pierre ^a   Brown, Ivor N ^a   Young, Douglas B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Drug screening; Luciferase; Pyrazinamide; Tuberculosis

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BCG VACCINATION; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; RECURRENCE RISK; T LYMPHOCYTE; TUBERCULOSIS;

ACTINOBACTERIA (CLASS); ANIMALIA; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0036774622     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/00221287-148-10-2929     Document Type: Article

References (18)

1. Barry, C. E., 3rd, Slayden, R. A., Sampson, A. E. & Lee, R. E. (2000). Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59, 221-231.
2. Cole, S. T., Brosch, R., Parkhill, J. & 39 other authors (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544.
3. Crowle, A. J., Sbarbaro, J. A. & May, M. H. (1986). Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 134, 1052-1055.
4. Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. (1999). Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (J Am Med Assoc) 282, 677-686.
5. Espinal, M. A., Laszlo, A., Simonson, L. & 9 other authors (2001). Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 344, 1294-1303.
6. Flynn, J. L. & Chan, J. (2001). Immunology of tuberculosis. Annu Rev Immunol 19, 93-129.
7. Glickman, M. S. & Jacobs, W. R., Jr (2001). Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 104, 477-485.
8. Global Alliance for TB Drug Development (2001). Scientific blueprint for tuberculosis drug development. Tuberculosis 81, Suppl 1, 1-52.
9. Heifets, L. & Lindholm-Levy, P. (1992). Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 145, 1223-1225.
10. Heifets, L., Higgins, M. & Simon, B. (2000). Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4, 491-495.
11. Klemens, S. P., Sharpe, C. A. & Cynamon, M. H. (1996). Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob Agents Chemother 40, 14-16.
12. McKinney, J. D. (2000). In vivo veritas: the search for TB drug targets goes live. Nat Med 6, 1330-1333.
13. Meighen, E. (1991). Molecular biology of bacterial luminescence. Microbiol Rev 55, 123-142.
14. Mitchison, D. A. (1985). The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225.
15. Orme, I. M. & Collins, F. M. (1994). Mouse model of tuberculosis. In Tuberculosis: Pathogenesis, Protection and Control, pp. 113-134. Edited by B. R. Bloom. Washington, DC: American Society for Microbiology.
16. Russell, D. G. (2001). Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2, 569-577.
17. Snewin, V. A., Gares, M. P., Gaora, P. O., Hasan, Z., Brown, I. N. & Young, D. B. (1999). Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect Immun 67, 4586-4593.
18. Wilson, M., DeRisi, J., Kristensen, H. H., Imboden, P., Rane, S., Brown, P. O. & Schoolnik, G. W. (1999). Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A 96, 12833-12838.